Israeli medical device maker Brainsway Ltd (TASE:BRIN) , has installed its new Deep Transcranial Magnetic Stimulation (dTMS) device for the treatment of depression at Premier Psychiatric Group‘s DTMS unit in St. Louis. This is Brainsway’s first such installation in the United States.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at email@example.com.
Brainsway has already begun deliveries of the new product in Sweden, deploying several dTMS systems at Karolinska University Hospital, a leading European institution. The systems there are expected to begin operation shortly, and will be utilized for treating seriously depressed patients. Sweden has one of the highest treatment resistant depression rates in the world, for both men and women.
Karolinska Hospital serves 1.3 million patients annually and is considered one of Scandinavia’s leading medical institutions, characterized by a high level of technological innovation. The Swedish implementation is another step toward establishing general clinical acceptance of Brainsway’s new method for treatment resistant depression.
A spokesperson for Premier Psychiatric Group said that their new partnership with Brainsway “brings the first Brainsway Deep Transcranial Magnetic Stimulation (dTMS) machine machine to Missouri that offers individuals who suffer from depression a noninvasive alternative to antidepressants.”
“The dTMS system is appealing to psychiatrists and patients because it offers a way to treat depression without medications that typically are taken throughout a patient’s life, ” said St. Louis psychiatrist Arturo C. Taca, … adding, “Electro-convulsive therapy (ECT) is the gold standard for treatment resistant depression but must be done in the hospital with anesthesia. dTMS is an outpatient procedure that has little disruption to a patient’s daily life with minimal side effects and is a safe, effective and practical way to offer a noninvasive treatment for major depression.”
Premier Psychiatric Group also added, “In other countries, mainly in Europe, Brainsway dTMS is frequently used to treat major depression but has been studied for a variety of other disorders as well, including Bipolar Depression, Chronic Pain, Smoking Cessation, Post Traumatic Stress Syndrome (PTSD), Autism, and Obsessive Compulsive Disorder (OCD).”